Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY (LLY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Lilly buys Siga's Priority Review voucher gained via smallpox approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/01/2018 | 03:11pm CET

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the first FDA awarded under its Material Threat Medical Countermeasure voucher program.

TPOXX, an oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga Gets Priority Review Voucher For First Approved Smallpox Drug").

Priority Review voucher prices have ranged from $67.5 million to $350 million since the first one was issued in 2009. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold one in July for $80.6 million (see "Voucher Equilibrium" and "Kyowa, Ultragenyx Sell Priority Review Voucher For $80.6M").

The medical countermeasure program was created under the 21st Century Cures Act, and awards vouchers for "medical products intended to diagnose, prevent or treat diseases or conditions associated with threats and emerging infectious diseases."

Siga was up $0.27 to $5.10 in early trading Thursday.

.

(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 2.18% 112.2 Delayed Quote.30.01%
KIRIN HOLDINGS CO LTD 0.12% 2552.5 End-of-day quote.-10.23%
KYOWA HAKKO KIRIN CO LTD 0.27% 2216 End-of-day quote.-0.27%
SIGA TECHNOLOGIES, INC. 1.62% 5.64 Delayed Quote.16.29%
ULTRAGENYX PHARMACEUTICAL INC 6.01% 51.29 Delayed Quote.4.31%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
11/14ELI LILLY AND : Reports Advances on Two Headache Treatments
DJ
11/14ELI LILLY AND : Lilly Submits New Drug Application to the FDA for Lasmiditan for..
PU
11/14ELI LILLY AND COMPANY : Ex-dividend day for
FA
11/13ELI LILLY AND : Is Migraine the First Front in the Battle Against Unresolved Pai..
PU
11/13AZ's Farxiga reduces heart failure, but misses on CV events
AQ
11/08ELI LILLY AND : Lilly to Participate in Credit Suisse 27th Annual Healthcare Con..
PR
11/08LILLY TRIALS BLOG HOME : We've Moved!
PU
11/07ELI LILLY AND : Profit doubles at Eli Lilly as drugmakers push Congress to fix `..
AQ
11/06ELI LILLY AND : Trulicity leads mixed third quarter for Lilly; shares sink
RE
11/06ELI LILLY AND COMPANY : Eli Lilly and Company Files 10-Q
EQ
More news
News from SeekingAlpha
11/14BIOTECH BIO SERIES #4 : Regeneron Is Not Done 
11/14Lilly submits U.S. marketing application for migraine med lasmiditan, Emgalit.. 
11/13ALDER BIOPHARMACEUTICALS : Pure Play Migraine Prevention Treatment In A Crowded .. 
11/13BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Merrimack's Struggle, Eli Lilly's Setback.. 
11/13Express Scripts launches new formulary aimed at reducing drug costs 
Financials ($)
Sales 2018 24 424 M
EBIT 2018 6 765 M
Net income 2018 3 304 M
Debt 2018 4 771 M
Yield 2018 2,15%
P/E ratio 2018 33,36
P/E ratio 2019 21,11
EV / Sales 2018 4,96x
EV / Sales 2019 4,88x
Capitalization 116 B
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 113 $
Spread / Average Target 3,0%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Michael R. Meadows VP & Chief Technology Officer
Aarti Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY30.01%116 324
JOHNSON & JOHNSON3.24%386 875
PFIZER18.47%248 878
NOVARTIS6.63%222 584
ROCHE HOLDING LTD.0.93%213 164
MERCK AND COMPANY31.67%192 662